US FDA Approves Novo Nordisk's Alhemo for Hemophilia

437 Views

Emedinexus 21 December 2024

The U.S. FDA has approved Novo Nordisks Alhemo, a subcutaneous injection for preventing or reducing bleeding episodes in hemophilia patients aged 12 and older. The drug is specifically designed for those with antibodies against traditional clotting factor replacement therapies.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.